Berberine: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Berberine |FDA_approval=No |used_for=Glioblastoma Multiforme (GBM) |OS_without=Not explicitly mentioned; refer to specific studies for detailed metrics. |OS_with=Studies suggest enhancement of temozolomide efficacy in resistant GBM cases, potentially improving overall survival rates. |clinical_trial_phase=Pre-clinical (in vitro and in vivo studies) |common_side_effects=Not specifically listed for GBM treatment; generally well-tolerated but can...") |
No edit summary |
||
| Line 9: | Line 9: | ||
|mechanism_of_action=Berberine exhibits anticancer activity by inhibiting cell proliferation and invasion, suppressing tumor angiogenesis, and inducing cell apoptosis. It has shown potential to sensitize temozolomide-resistant GBM cells, suggesting its utility in overcoming treatment resistance. | |mechanism_of_action=Berberine exhibits anticancer activity by inhibiting cell proliferation and invasion, suppressing tumor angiogenesis, and inducing cell apoptosis. It has shown potential to sensitize temozolomide-resistant GBM cells, suggesting its utility in overcoming treatment resistance. | ||
|notes=Recent studies underscore Berberine's promising role against GBM, especially in temozolomide-resistant cases. Its broad pharmacological actions against cancer, including GBM, spotlight its potential as a multi-targeted therapeutic agent. Despite the promising laboratory and animal model results, further research is needed to fully understand its clinical implications and optimal usage in GBM treatment. | |notes=Recent studies underscore Berberine's promising role against GBM, especially in temozolomide-resistant cases. Its broad pharmacological actions against cancer, including GBM, spotlight its potential as a multi-targeted therapeutic agent. Despite the promising laboratory and animal model results, further research is needed to fully understand its clinical implications and optimal usage in GBM treatment. | ||
|category=Nutraceuticals | |category=Nutraceuticals and herbals | ||
}} | }} | ||
Revision as of 05:31, 21 March 2024
| Property | Information |
|---|---|
| Drug Name | Berberine |
| FDA Approval | No |
| Used for | Glioblastoma Multiforme (GBM) |
| Clinical Trial Phase | Pre-clinical (in vitro and in vivo studies) |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Not specifically listed for GBM treatment; generally well-tolerated but can include gastrointestinal discomfort at high doses. |
| OS without | Not explicitly mentioned; refer to specific studies for detailed metrics. |
| OS with | Studies suggest enhancement of temozolomide efficacy in resistant GBM cases, potentially improving overall survival rates. |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | Not rated |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Recent studies underscore Berberine's promising role against GBM, especially in temozolomide-resistant cases. Its broad pharmacological actions against cancer, including GBM, spotlight its potential as a multi-targeted therapeutic agent. Despite the promising laboratory and animal model results, further research is needed to fully understand its clinical implications and optimal usage in GBM treatment.
From Ben Williams Book: Not specified
Loading comments...
